

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

FRIDAY, JANUARY 31, 1975

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 10:07 a.m., in room 1114, Dirksen Senate Office Building, Senator Gaylord Nelson (chairman of the full committee) presiding.

Present: Senator Nelson.

Also present: Benjamin Gordon, staff economist, and Kay Klatt, research assistant.

The CHAIRMAN. Today the Monopoly Subcommittee of the Senate Small Business Committee is resuming its hearings on the oral hypoglycemic drugs initiated on September 18, 19, and 30 of last year.

Our witnesses today will discuss recent studies dealing with the safety, efficacy and usefulness of this class of drugs. The list of witnesses includes four members of the committee selected by the internationally renowned Biometric Society as well as a member of the Mayo Clinic.

Additional witnesses to appear are Mr. Neil Chayet and Dr. Robert Bradley, counsel and chairman respectively of the Committee on the Care of the Diabetic.

Our first witness this morning is Dr. Colin White, professor of public health, Yale University School of Medicine, New Haven, Conn.

Dr. White, your statement will be printed in full in the record, and you may present it however you desire, and extemporize as much as you wish.

Would you identify the organization you represent for the record, or first, for the reporter. Perhaps each of you, starting on my far right, would identify yourself for the reporter, so if you address yourself to some question we shall be able to identify you.

Dr. MEIER. I am Paul Meier, professor of statistics at the University of Chicago.

Dr. RICKETTS. Dr. Ricketts, University of Chicago.

Dr. WHITE. Colin White, professor of public health, Yale University.

Dr. ZELLEN. Marvin Zelen, professor of statistical science, State University of New York, Buffalo.